Good ideas and conversation. No ads, no tracking. Login or Take a Tour!
mk · 1771 days ago · link · · parent · post: A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down
It’s not possible given his experience that he’s naive about the FDA. His investors certainly are not. I’ve met with Arboretum. They likely know most of the relevant folk at the FDA. I’d say the opposite is more likely. He might know the FDA very well. This is likely a chemistry/ip/regulatory arbitrage play. You make a drug that is like another, show it is very much like the other to lower approval barriers, get it on the market at a cut rate, then undercut everyone.Other big venture firms, including GV, a16z, Casdin Capital, Section 32, Nextech, and Arboretum Ventures, have also signed on.